Rockefeller Capital Management
IOVA icon

Rockefeller Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Rockefeller Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Sell
34,982
-20,486
-37% -$77.8K ﹤0.01% 2770
2026
Q1 		$195K Buy
55,468
+4,742
+9% +$15.2K ﹤0.01% 2513
2025
Q4 		$138K Buy
50,726
+33,091
+188% +$76.6K ﹤0.01% 2548
2025
Q3 		$38.3K Buy
+17,635
New +$41.6K ﹤0.01% 3039
2025
Q1 		– Sell
-46,417
Closed -$343K – 1701
2024
Q4 		$343K Buy
46,417
+3,266
+8% +$30.3K ﹤0.01% 1573
2024
Q3 		$405K Buy
43,151
+239
+0.6% +$2.26K ﹤0.01% 1492
2024
Q2 		$344K Buy
42,912
+361
+0.8% +$3.87K ﹤0.01% 1525
2024
Q1 		$631K Buy
42,551
+2,678
+7% +$31.2K ﹤0.01% 1398
2023
Q4 		$324K Buy
+39,873
New +$209K ﹤0.01% 1448
2023
Q3 		– Sell
-37,758
Closed -$266K – 1661
2023
Q2 		$266K Buy
37,758
+1,385
+4% +$9.91K ﹤0.01% 1552
2023
Q1 		$221K Buy
36,373
+2,000
+6% +$13.8K ﹤0.01% 1765
2022
Q4 		$219K Buy
34,373
+3,500
+11% +$27.3K ﹤0.01% 1624
2022
Q3 		$295K Sell
30,873
-682
-2% -$7.87K ﹤0.01% 1474
2022
Q2 		$347K Buy
31,555
+8,871
+39% +$116K ﹤0.01% 1413
2022
Q1 		$377K Sell
22,684
-308
-1% -$4.76K ﹤0.01% 1430
2021
Q4 		$438K Buy
22,992
+22,642
+6,469% +$498K ﹤0.01% 1366
2021
Q3 		$8K Sell
350
-150
-30% -$3.53K ﹤0.01% 2992
2021
Q2 		$13K Hold
500
– – ﹤0.01% 2669
2021
Q1 		$15K Hold
500
– – ﹤0.01% 2412
2020
Q4 		$23K Sell
500
-412
-45% -$16.4K ﹤0.01% 1952
2020
Q3 		$30K Buy
912
+49
+6% +$1.5K ﹤0.01% 1655
2020
Q2 		$24K Sell
863
-67
-7% -$2.2K ﹤0.01% 1617
2020
Q1 		$28K Buy
930
+180
+24% +$4.77K ﹤0.01% 1406
2019
Q4 		$21K Buy
+750
New +$17.1K ﹤0.01% 1378
2019
Q2 		– Sell
-82
Closed -$1K – 1802
2019
Q1 		$1K Buy
+82
New +$796 ﹤0.01% 1860

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Rockefeller Capital Management's IOVA Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 37% in Q2 2026, selling an estimated $77.8K and leaving 34,982 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #2770.

Rockefeller Capital Management first reported a position in IOVA in Q1 2019 and has held it in 25 quarters since. The position peaked at $631K in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Rockefeller Capital Management held 34,982 shares of Iovance Biotherapeutics worth $146K as of Q2 2026.
  • Rockefeller Capital Management sold 20,486 Iovance Biotherapeutics shares in Q2 2026, an estimated $77.8K.
  • Iovance Biotherapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2770 holding.
  • Rockefeller Capital Management first reported a position in Iovance Biotherapeutics in Q1 2019 and has held it in 25 quarters since.
  • Rockefeller Capital Management's Iovance Biotherapeutics position peaked at $631K in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.